Pfizer Inc
* Besponsa® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
* Pfizer Inc - Prescription Drug User Fee Act (PDUFA) goal date for a decision by FDA is august 2017. Source text for Eikon: Further company coverage:
